Exosomal proteins as prostate cancer biomarkers in urine: From mass spectrometry discovery to immunoassay-based validation

European Journal of Pharmaceutical Sciences

Volumn 98, Issue , 2017, Pages 80-85

  Wang, Ling ^a,b   Skotland, Tore ^a,b   Berge, Viktor ^a   Sandvig, Kirsten ^a,b,c   Llorente, Alicia ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

Diagnostics; Exosomes; Extracellular vesicles; Immunology based assays; Noninvasive biomarkers; Prostate cancer; Urine

Indexed keywords

BIOLOGICAL MARKER; FLOTILLIN 2; PROTEIN DERIVATIVE; PROTEIN LAMTOR1; PROTEIN RAB3B; PROTEIN TMEM256; RAB PROTEIN; UNCLASSIFIED DRUG; CARRIER PROTEIN; FLOTILLINS; MEMBRANE PROTEIN; P27RF-RHO PROTEIN, HUMAN; RAB3B PROTEIN, HUMAN; TMEM26 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; EXOSOME; HUMAN; IMMUNOASSAY; MALE; MASS SPECTROMETRY; MIDDLE AGED; PRIORITY JOURNAL; PROSTATE CANCER; SENSITIVITY AND SPECIFICITY; URINALYSIS; VALIDATION STUDY; WESTERN BLOTTING; AGED; METABOLISM; PROSTATE TUMOR; REPRODUCIBILITY;

ADULT; AGED; BIOMARKERS, TUMOR; CARRIER PROTEINS; EXOSOMES; HUMANS; IMMUNOASSAY; MALE; MASS SPECTROMETRY; MEMBRANE PROTEINS; MIDDLE AGED; PROSTATIC NEOPLASMS; RAB3 GTP-BINDING PROTEINS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 85001104698     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2016.09.023     Document Type: Article

References (31)

1. Colombo, M., Raposo, G., Thery, C., Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu. Rev. Cell Dev. Biol. 30 (2014), 255–289.
2. Crutchfield, C.A., Thomas, S.N., Sokoll, L.J., Chan, D.W., Advances in mass spectrometry-based clinical biomarker discovery. Clin. Proteomics, 13, 2016, 1.
3. Dijkstra, S., Birker, I.L., Smit, F.P., Leyten, G.H., de Reijke, T.M., van Oort, I.M., Mulders, P.F., Jannink, S.A., Schalken, J.A., Prostate cancer biomarker profiles in urinary sediments and exosomes. J. Urol. 191 (2014), 1132–1138.
4. Duijvesz, D., Versluis, C.Y., van der Fels, C.A., Vredenbregt-van den Berg, M.S., Leivo, J., Peltola, M.T., Bangma, C.H., Pettersson, K.S., Jenster, G., Immuno-based detection of extracellular vesicles in urine as diagnostic marker for prostate cancer. Int. J. Cancer 137 (2015), 2869–2878.
5. Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D.M., Forman, D., Bray, F., Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136 (2015), E359–E386.
6. Gillette, M.A., Carr, S.A., Quantitative analysis of peptides and proteins in biomedicine by targeted mass spectrometry. Nat. Methods 10 (2013), 28–34.
7. Huebner, A.R., Somparn, P., Benjachat, T., Leelahavanichkul, A., Avihingsanon, Y., Fenton, R.A., Pisitkun, T., Exosomes in urine biomarker discovery. Adv. Exp. Med. Biol. 845 (2015), 43–58.
8. Kim, Y., Ignatchenko, V., Yao, C.Q., Kalatskaya, I., Nyalwidhe, J.O., Lance, R.S., Gramolini, A.O., Troyer, D.A., Stein, L.D., Boutros, P.C., Medin, J.A., Semmes, O.J., Drake, R.R., Kislinger, T., Identification of differentially expressed proteins in direct expressed prostatic secretions of men with organ-confined versus extracapsular prostate cancer. Mol. Cell. Proteomics 11 (2012), 1870–1884.
9. Llorente, A., Skotland, T., Sylvanne, T., Kauhanen, D., Rog, T., Orlowski, A., Vattulainen, I., Ekroos, K., Sandvig, K., Molecular lipidomics of exosomes released by PC-3 prostate cancer cells. Biochim. Biophys. Acta 1831 (2013), 1302–1309.
10. Makawita, S., Diamandis, E.P., The bottleneck in the cancer biomarker pipeline and protein quantification through mass spectrometry-based approaches: current strategies for candidate verification. Clin. Chem. 56 (2010), 212–222.
11. Martins, V.R., Dias, M.S., Hainaut, P., Tumor-cell-derived microvesicles as carriers of molecular information in cancer. Curr. Opin. Oncol. 25 (2013), 66–75.
12. McKiernan, J., Donovan, M.J., O'Neill, V., Bentink, S., Noerholm, M., Belzer, S., Skog, J., Kattan, M.W., Partin, A., Andriole, G., Brown, G., Wei, J.T., Thompson, I.M. Jr., Carroll, P., A novel urine exosome gene expression assay to predict high-grade prostate cancer at initial biopsy. JAMA Oncol. 2 (2016), 882–889.
13. Mermelekas, G., Vlahou, A., Zoidakis, J., SRM/MRM targeted proteomics as a tool for biomarker validation and absolute quantification in human urine. Expert. Rev. Mol. Diagn., 15, 2015, 1454.
14. Mitchell, P.J., Welton, J., Staffurth, J., Court, J., Mason, M.D., Tabi, Z., Clayton, A., Can urinary exosomes act as treatment response markers in prostate cancer?. J. Transl. Med., 7, 2009, 4.
15. Murphy, L., Prencipe, M., Gallagher, W.M., Watson, R.W., Commercialized biomarkers: new horizons in prostate cancer diagnostics. Expert. Rev. Mol. Diagn., 15, 2015, 503.
16. Nilsson, J., Skog, J., Nordstrand, A., Baranov, V., Mincheva-Nilsson, L., Breakefield, X.O., Widmark, A., Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer. Br. J. Cancer 100 (2009), 1603–1607.
17. Øverbye, A., Skotland, T., Koehler, C.J., Thiede, B., Seierstad, T., Berge, V., Sandvig, K., Llorente, A., Identification of prostate cancer biomarkers in urinary exosomes. Oncotarget 6 (2015), 30357–30376.
18. Parker, C.E., Borchers, C.H., Mass spectrometry based biomarker discovery, verification, and validation - quality assurance and control of protein biomarker assays. Mol. Oncol. 8 (2014), 840–858.
19. Pocsfalvi, G., Stanly, C., Vilasi, A., Fiume, I., Capasso, G., Turiak, L., Buzas, E.I., Vekey, K., Mass spectrometry of extracellular vesicles. Mass Spectrom. Rev. 35 (2016), 3–21.
20. Prensner, J.R., Rubin, M.A., Wei, J.T., Chinnaiyan, A.M., Beyond PSA: the next generation of prostate cancer biomarkers. Sci. Transl. Med., 4, 2012, 127rv3.
21. Rak, J., Extracellular vesicles - biomarkers and effectors of the cellular interactome in cancer. Front. Pharmacol., 4, 2013, 21.
22. Raposo, G., Stoorvogel, W., Extracellular vesicles: exosomes, microvesicles, and friends. J. Cell Biol. 200 (2013), 373–383.
23. Rodriguez-Suarez, E., Gonzalez, E., Hughes, C., Conde-Vancells, J., Rudella, A., Royo, F., Palomo, L., Elortza, F., Lu, S.C., Mato, J.M., Vissers, J.P., Falcon-Perez, J.M., Quantitative proteomic analysis of hepatocyte-secreted extracellular vesicles reveals candidate markers for liver toxicity. J. Proteome 103 (2014), 227–240.
24. Sheridan, C., Exosome cancer diagnostic reaches market. Nat. Biotechnol. 34 (2016), 359–360.
25. Simpson, R.J., Lim, J.W., Moritz, R.L., Mathivanan, S., Exosomes: proteomic insights and diagnostic potential. Expert. Rev. Proteomics 6 (2009), 267–283.
26. Tan, P.Y., Chang, C.W., Chng, K.R., Wansa, K.D., Sung, W.K., Cheung, E., Integration of regulatory networks by NKX3-1 promotes androgen-dependent prostate cancer survival. Mol. Cell. Biol. 32 (2012), 399–414.
27. Thery, C., Amigorena, S., Raposo, G., Clayton, A., Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr. Protoc. Cell Biol., 2006 Chapter 3:Unit 3.22.
28. Tillman, J.E., Yuan, J., Gu, G., Fazli, L., Ghosh, R., Flynt, A.S., Gleave, M., Rennie, P.S., Kasper, S., DJ-1 binds androgen receptor directly and mediates its activity in hormonally treated prostate cancer cells. Cancer Res. 67 (2007), 4630–4637.
29. Wang, X., Yang, Q., Guo, L., Li, X.H., Zhao, X.H., Song, L.B., Lin, H.X., Flotillin-2 is associated with breast cancer progression and poor survival outcomes. J. Transl. Med., 11, 2013, 190.
30. Wood, S.L., Knowles, M.A., Thompson, D., Selby, P.J., Banks, R.E., Proteomic studies of urinary biomarkers for prostate, bladder and kidney cancers. Nat. Rev. Urol. 10 (2013), 206–218.
31. Zhu, Z., Wang, J., Sun, Z., Sun, X., Wang, Z., Xu, H., Flotillin2 expression correlates with HER2 levels and poor prognosis in gastric cancer. PLoS One, 8, 2013, e62365.